Vol. 22/No. 19

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

Hepatocellular cancer, the most common primary liver malignancy, is the fourth-leading cause of cancer-related deaths globally.

Ahmet Sezer, MD, discusses how the approval of cemiplimab could potentially make a huge impact for patients with advanced non–small cell lung cancer.

The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.

The tide is starting to turn toward more effective frontline systemic therapies for patients with unresectable hepatocellular carcinoma as a result of the introduction of a novel immune-oncology combination.

The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.